Hikma delivers strong 2023 performance and positive outlook for 2024
Amman, 22 February 2024 – Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2023.
The Group reported revenue growth of 14% (15% in constant currency) to $2.875 billion )compared to $2.517 billion in 2022). In 2023, we continued to deliver on our purpose of making high quality medicines accessible to those that need them. All three of our businesses grew, driven by new launches, partnerships and a focus on delivering more from our existing portfolio. Riad Mishlawi was appointed CEO in September 2023, and under this new leadership, with a refreshed, ......Read More
Thursday, February 22, 2024